Krishna Abhishek, Jayachandran Mamatha, Sacheendran Dhanya, Simon Paul, George Thomas, Palatty Princy Louis, Baliga Manjeshwar Shrinath
Department of Radiation Oncology, Mysore Medical College and Research Institute, Irwin Road, Mysuru, Karnataka India.
Department of Pharmacology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Ernakulam, Kerala India.
J Obstet Gynaecol India. 2024 Dec;74(6):489-497. doi: 10.1007/s13224-023-01905-1. Epub 2024 Jan 29.
BACKGROUND/PURPOSE OF THE STUDY: Globally, gynaecological cancer is an important malignancy and chemotherapy is an essential component of the standard treatment modality. The purpose of the study was to determine the cost minimization analysis by comparing the price of the most expensive and least expensive branded drugs used in the treatment of gynaecological cancer in India, considering body surface area relevant to the Indian context.
This was a conventional pharmacoeconomic study designed to determine the lowest possible cost. We compared the prices of the most and least expensive branded drugs from the Current Index of Medical Stores. Also cost of anticancer drugs available in Jan Aushadi stores was also considered for the study. The cost difference, cost ratio and percentage of change in costs were all calculated in accordance with the standard formula. All drugs and the therapeutic regimens (chemo-radiation regimens and chemotherapy) used in the treatment of gynaecological cancer were analysed to understand the cost difference for the treatment regimens.
The results indicate that while all anticancer drugs used in the treatment of gynecalogical cancers were available in both costliest and cheapest brand category, bevacizumab and liposomal doxorubicin were unavailable in the Jan Aushadhi stores. The paclitaxel carboplatin regimen had the biggest cost variation between the costliest brand and Jan Aushadhi (Rs. 81,273). The paclitaxel carboplatin bevacizumab regimen had the greatest cost difference (Rs 14,61,646), while weekly cisplatin (Rs 4017) showed less variance. When replacing the most expensive branded pharmaceuticals with cheaper brands or Jan Aushadhi drugs, the cisplatin paclitaxel regimen cost 4.8 to 9.5 times less (Rs 107,655 vs Rs 54,414.4 vs Rs 13,464). For single-agent chemotherapy, substituting the most expensive branded medications with cheaper or Jan Aushadhi products saved money as follows: paclitaxel 37,266 to 55,149; carboplatin Rs 5,556 to Rs 26,124; and liposomal doxorubicin 22,804.
The results indicate a huge difference between the costly and the cheapest branded and Jan Aushadhi anticancer drugs and based regimens in treating gynaecological cancer.
研究背景/目的：在全球范围内，妇科癌症是一种重要的恶性肿瘤，化疗是标准治疗模式的重要组成部分。本研究的目的是通过比较印度用于治疗妇科癌症的最昂贵和最便宜品牌药物的价格，并考虑与印度情况相关的体表面积，来确定成本最小化分析。
这是一项旨在确定最低可能成本的传统药物经济学研究。我们比较了《医疗商店当前指数》中最昂贵和最便宜品牌药物的价格。同时，本研究还考虑了平价药品商店中抗癌药物的成本。成本差异、成本比率和成本变化百分比均按照标准公式计算。对用于治疗妇科癌症的所有药物和治疗方案（放化疗方案和化疗）进行分析，以了解治疗方案的成本差异。
结果表明，虽然用于治疗妇科癌症的所有抗癌药物在最贵和最便宜品牌类别中均有供应，但贝伐单抗和脂质体阿霉素在平价药品商店中没有。紫杉醇-卡铂方案在最贵品牌和平价药品商店之间的成本差异最大（81,273卢比）。紫杉醇-卡铂-贝伐单抗方案的成本差异最大（14,61,646卢比），而每周使用顺铂（4017卢比）的差异较小。当用更便宜的品牌或平价药品商店的药物替代最昂贵的品牌药物时，顺铂-紫杉醇方案的成本降低了4.8至9.5倍（107,655卢比对54,414.4卢比对13,464卢比）。对于单药化疗，用更便宜的或平价药品商店的产品替代最昂贵的品牌药物节省的费用如下：紫杉醇37,266至55,149卢比；卡铂5,556至26,124卢比；脂质体阿霉素22,804卢比。
结果表明，在治疗妇科癌症方面，昂贵和最便宜的品牌及平价药品商店的抗癌药物和基于这些药物的治疗方案之间存在巨大差异。
